Rolf Hultsch
PathologyOncologyChemotherapyPancreatic cancerMedicine
What is this?
Publications 3
#2Rolf HultschH-Index: 1
Last. Erkut BorazanciH-Index: 8
view all 6 authors...
Background: Thrombocytopenia may be a concern in treating pancreatic ductal adenocarcinomas (PDAC). Due to anatomic position these tumors commonly cause narrowing or occlusion of the splenic vein which may lead to hypersplenism and thrombocytopenia due to sequestration. PDAC patients with thrombocytopenia have limited options for treatment. Partial splenic embolization (PSE) is a procedure developed as an alternative to splenectomy in individuals with hypersplenism. The purpose of our study was ...
#1Vincent Chung (City of Hope National Medical Center)H-Index: 15
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
view all 20 authors...
TPS4154Background: Pancreatic cancer remains a deadly disease and despite advances in chemotherapy treatment, survival for most patients is still less than one year. Refractory pancreatic cancer ha...
1 CitationsSource
#1Hani M. Babiker (UA: University of Arizona)H-Index: 8
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
view all 14 authors...
e15150Background: Patients without palpable lesions who are candidates for intratumoral immunotherapy may need D/V IG agent delivery. Novel immuno-oncology (I-O) agents requiring ITI highlight the ...